These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30501110)

  • 1. Design of a Novel and Selective IRAK4 Inhibitor Using Topological Water Network Analysis and Molecular Modeling Approaches.
    Lee MH; Balupuri A; Jung YR; Choi S; Lee A; Cho YS; Kang NS
    Molecules; 2018 Nov; 23(12):. PubMed ID: 30501110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
    Bhide RS; Keon A; Weigelt C; Sack JS; Schmidt RJ; Lin S; Xiao HY; Spergel SH; Kempson J; Pitts WJ; Carman J; Poss MA
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4908-4913. PubMed ID: 28947151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
    McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
    Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of IRAK4 inhibitor activity prediction model based on machine learning.
    Zhao Y; Wan Q; He X
    Mol Divers; 2024 Aug; 28(4):2289-2300. PubMed ID: 38970641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
    Lee KL; Ambler CM; Anderson DR; Boscoe BP; Bree AG; Brodfuehrer JI; Chang JS; Choi C; Chung S; Curran KJ; Day JE; Dehnhardt CM; Dower K; Drozda SE; Frisbie RK; Gavrin LK; Goldberg JA; Han S; Hegen M; Hepworth D; Hope HR; Kamtekar S; Kilty IC; Lee A; Lin LL; Lovering FE; Lowe MD; Mathias JP; Morgan HM; Murphy EA; Papaioannou N; Patny A; Pierce BS; Rao VR; Saiah E; Samardjiev IJ; Samas BM; Shen MWH; Shin JH; Soutter HH; Strohbach JW; Symanowicz PT; Thomason JR; Trzupek JD; Vargas R; Vincent F; Yan J; Zapf CW; Wright SW
    J Med Chem; 2017 Jul; 60(13):5521-5542. PubMed ID: 28498658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel benzenediamine derivate rescued mice from experimental sepsis by attenuating proinflammatory mediators via IRAK4.
    Dou H; Song Y; Liu X; Yang L; Jiang N; Chen D; Li E; Tan R; Hou Y
    Am J Respir Cell Mol Biol; 2014 Aug; 51(2):191-200. PubMed ID: 24588661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
    Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of binding site waters on the activity/selectivity trade-off of Janus kinase 2 (JAK2) inhibitors.
    Egyed A; Bajusz D; Keserű GM
    Bioorg Med Chem; 2019 Apr; 27(8):1497-1508. PubMed ID: 30833158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
    Chaudhary D; Robinson S; Romero DL
    J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of human IRAK1.
    Wang L; Qiao Q; Ferrao R; Shen C; Hatcher JM; Buhrlage SJ; Gray NS; Wu H
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13507-13512. PubMed ID: 29208712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).
    Seganish WM
    Expert Opin Ther Pat; 2016 Aug; 26(8):917-32. PubMed ID: 27310003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtual screening based on pharmacophore model followed by docking simulation studies in search of potential inhibitors for p38 map kinase.
    Shahlaei M; Doosti E
    Biomed Pharmacother; 2016 May; 80():352-372. PubMed ID: 27133076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing and Validating Cellular Functional Target Engagement Assay for Selective IRAK4 Inhibitor Discovery.
    Chen Y; Sun D; Yang R; Lim J; Sondey C; Presland J; Rakhilina L; Addona G; Kariv I; Chen H
    SLAS Discov; 2021 Sep; 26(8):1040-1054. PubMed ID: 34130529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for the inhibitor recognition of human Lyn kinase domain.
    Miyano N; Kinoshita T; Nakai R; Kirii Y; Yokota K; Tada T
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6557-60. PubMed ID: 19857964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
    Zhao H; Huang D; Caflisch A
    ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophoric Site Identification and Inhibitor Design for Autotaxin.
    Lee MH; Lee DY; Balupuri A; Jeong JW; Kang NS
    Molecules; 2019 Aug; 24(15):. PubMed ID: 31374894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
    Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M
    J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors.
    Hanisak J; Seganish WM; McElroy WT; Tang H; Zhang R; Tsui HC; Fischmann T; Tulshian D; Tata J; Sondey C; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4250-5. PubMed ID: 27476420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors.
    Hoi PM; Li S; Vong CT; Tseng HH; Kwan YW; Lee SM
    Methods; 2015 Jan; 71():85-91. PubMed ID: 25239735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors.
    Kaur M; Singh PK; Singh M; Bahadur R; Silakari O
    Mol Divers; 2018 Feb; 22(1):95-112. PubMed ID: 29138965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.